Lead Product(s) : Fosigotifator
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Calico Announces Fosigotifator Selected for FDA Pilot Program for White Matter Disease
Details : ABBV-CLS-7262 (fosigotifator) is an eIF2B activator, a factor that is essential for protein synthesis and a key regulator of the ISR. It is being investigated for vanishing white matter disease.
Brand Name : ABBV-CLS-7262
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 07, 2024
Lead Product(s) : Fosigotifator
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?